Impact of Vancomycin Exposure on Outcomes in Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia: Support for Consensus Guidelines Suggested Targets
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
BACKGROUND: High rates of vancomycin failure in methicillin-resistant Staphylococcus aureus (MRSA) infections have been increasingly reported over time. The primary objective of our study was to determine the impact of vancomycin exposure and outcomes in patients with MRSA bacteremia initially treated with vancomycin. METHODS: This was a single-center retrospective analysis of 320 patients with documented MRSA bacteremia initially treated with vancomycin from January 2005 through April 2010. Two methods of susceptibility, Etest and broth microdilution, were performed for all isolates to determine the correlation of susceptibility testing to patient outcomes. RESULTS: Among a cohort of 320 patients, more than half (52.5%) experienced vancomycin failure. Independent predictors of vancomycin failure in logistic regression included infective endocarditis (adjusted odds ratio [AOR], 4.55; 95% confidence interval [CI], 2.26-9.15), nosocomial-acquired infection (AOR, 2.19; 95% CI, 1.21-3.97), initial vancomycin trough <15 mg/L (AOR, 2.00; 95% CI, 1.25-3.22), and vancomycin minimum inhibitory concentration (MIC) >1 mg/L by Etest (AOR, 1.52; 95% CI, 1.09-2.49). With use of Classification and Regression Tree (CART) analysis, patients with vancomycin area under the curve at 24 h (AUC(24h)) to MIC ratios <421 were found to have significantly higher rates of failure, compared with patients with AUC(24h) to MIC ratios >421 (61.2% vs 48.6%; P = .038). CONCLUSIONS: In light of the high failure rates associated with this antimicrobial, optimizing the pharmacokinetic/pharmacodynamic properties of vancomycin by targeting higher trough values of 15-20 mg/L and AUC(24h)/MIC ratios ≥400 in selected patients should be considered.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
System, A. R. F. T. N. (2003) · American Journal of Infection Control · doi:10.1016/j.ajic.2003.09.002 · Cited by 2,915
Lina, G., Piemont, Y., Godail-Gamot, F., Bes, M., Peter, M.-O., Gauduchon, V., Vandenesch, F., & Etienne, J. (1999) · Clinical Infectious Diseases · doi:10.1086/313461 · Cited by 2,489 · cited 1×
“genes encoding Panton–Valentine leukocidin, and agr group and agr function were determined using previously described methods [24, 25].”
MethodSystem, A. R. F. T. N. (2004) · American Journal of Infection Control · doi:10.1016/j.ajic.2004.10.001 · Cited by 2,342
Federal Funding for the Study of Antimicrobial Resistance in Nosocomial Pathogens: No ESKAPE
Rice, L. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/533452 · Cited by 2,310
Zhang, K., McClure, J.-A., Elsayed, S., Louie, T., & Conly, J. M. (2005) · Journal of Clinical Microbiology · doi:10.1128/jcm.43.10.5026-5033.2005 · Cited by 1,037
Cosgrove, S. E., Qi, Y., Kaye, K. S., Harbarth, S., Karchmer, A. W., & Carmeli, Y. (2005) · Infection Control & Hospital Epidemiology · doi:10.1086/502522 · Cited by 856
Levine, D. P. (2006) · Clinical Infectious Diseases · doi:10.1086/491709 · Cited by 838
Self-citationSakoulas, G., Moise-Broder, P. A., Schentag, J., Forrest, A., Moellering, R. C., & Eliopoulos, G. M. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.6.2398-2402.2004 · Cited by 836
The emergence and evolution of methicillin-resistant Staphylococcus aureus
Hiramatsu, K., Cui, L., Kuroda, M., & Ito, T. (2001) · Trends in Microbiology · doi:10.1016/s0966-842x(01)02175-8 · Cited by 825
Cited by
Items 101–200 of 460
McNeil, J. C., Kok, E. Y., Forbes, A., Lamberth, L. B., Hultén, K. G., Vallejo, J. G., Mason, E. O., & Kaplan, S. L. (2015) · The Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000000991 · Cited by 53
“Studies in adults with bacteremia and endocarditis have shown improved clinical outcomes when vancomycin troughs are >15 μg/mL.(2,3) For severe MRSA infections in adults, the Infectious Diseases Society of America recommends targeting vancomycin serum trough concentrations between 15 and 20 μg/mL.”
BackgroundArshad, S., Huang, V., Hartman, P., Perri, M. B., Moreno, D., & Zervos, M. (2017) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2017.01.019 · Cited by 56
“Methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections (BSI) continue to have high mortality, with rates of 20–30% reported in recent studies.(1) According to the US Centers for Disease Control and Prevention (CDC), an attributable 94 360 invasive infections and 18 650 deaths occur annually in the U…”
BackgroundOptimization of time to initial vancomycin target trough improves clinical outcomes
Cardile, A. P., Tan, C., Lustik, M. B., Stratton, A., Madar, C., Elegino, J., & Hsue, G. (2015) · SpringerPlus · doi:10.1186/s40064-015-1146-9 · Cited by 49
Antibiotic dose optimization in critically ill patients
Cotta, M. O., Roberts, J. A., & Lipman, J. (2015) · Medicina Intensiva · doi:10.1016/j.medin.2015.07.009 · Cited by 55
Lee, D., Murakami, Y., Andes, D. R., & Craig, W. A. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00362-12 · Cited by 51
“Two retrospective reviews of MRSA bacteremia with and without associated endocarditis treated with VAN identified AUC0-24/MIC values of 211 and 421 by classification and regression tree (CART) analysis that best differentiated success from failure in their respective patient populations (27, 48).”
BackgroundMethodGhosh, N., Chavada, R., Maley, M. W., & van Hal, S. J. (2014) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12695 · Cited by 47
“observed in MRSA bacteraemia studies [9–12].”
BackgroundMethodResultInfluentialLiang, X., Fan, Y., Yang, M., Zhang, J., Wu, J., Yu, J., Tao, J., Lü, G., Zhang, H., Wang, R., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy680 · Cited by 47
Multidrug-Resistant Organisms and Antibiotic Management
Barie, P. S. (2012) · Surgical Clinics of North America · doi:10.1016/j.suc.2012.01.015 · Cited by 53
Cost–benefit analysis comparing trough, two-level AUC and Bayesian AUC dosing for vancomycin
Lee, B. V., Fong, G. R., Bolaris, M., Neely, M. N., Minejima, E., Kang, A. Y., Lee, G., & Gong, C. L. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.11.008 · Cited by 46
Hahn, A., Frenck, R. W., Staat, M. A., Zou, Y., & Vinks, A. A. T. M. M. (2015) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000190 · Cited by 45
“In the study by Kullar et al,11 vancomycin treatment failure was defined as bacteremia .7 days, recurrence of bacteremia within 30 days, or 30-day mortality.”
BackgroundCampbell, M. L., Marchaim, D., Pogue, J. M., Sunkara, B., Bheemreddy, S., Bathina, P., Pulluru, H., Chugh, N., Wilson, M. N., Moshos, J. A., et al. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1r211 · Cited by 50
Self-citationPharmacokinetics and pharmacodynamics of peptide antibiotics
Bian, X., Qu, X., Zhang, J., Nang, S. C., Bergen, P. J., Zhou, Q. T., Chan, H., Feng, M., & Li, J. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114171 · Cited by 47
Mavros, M. N., Tansarli, G. S., Vardakas, K. Z., Rafailidis, P. I., Karageorgopoulos, D. E., & Falagas, M. E. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2012.07.023 · Cited by 45
Current and prospective treatments for multidrug-resistant gram-positive infections
Rybak, J. M., Barber, K. E., & Rybak, M. J. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.820276 · Cited by 45
“Unfortunately, the inability to detect hVISA is likely contributing to the rise in vancomycin treatment failures being reported with serious infections involving a high bacterial burden such as complicated bacteremia including infective endocarditis [23-25].”
BackgroundSelf-citationZhang, Y., Wang, T., Zhang, D., You, H., Dong, Y., Liu, Y., Du, Q., Sun, D., Zhang, T., & Dong, Y. (2020) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000000750 · Cited by 44
Dilworth, T. J., Sliwinski, J., Ryan, K. L., Dodd, M., & Mercier, R.-C. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01888-13 · Cited by 46
“VAN treatment has also been associated with high clinical failure rates in patients with MRSA isolates susceptible to VAN (11, 12).”
BackgroundJorgensen, S. C. J., Murray, K. P., Lagnf, A. M., Melvin, S. M., Bhatia, S., Shamim, M.-D., Smith, J. R., Brade, K. D., Simon, S. P., Nagel, J. L., et al. (2020) · Infectious Diseases and Therapy · doi:10.1007/s40121-019-00278-1 · Cited by 46
Self-citationWhen and How to Use MIC in Clinical Practice?
Magréault, S., Jauréguy, F., Carbonnelle, É., & Zahar, J. (2022) · Antibiotics · doi:10.3390/antibiotics11121748 · Cited by 62
“Moreover, a few studies have reported poorer clinical outcomes and increased mortality associated with vancomycin MIC creep [22,23].”
BackgroundAntonelli, M. M., Bonten, M. J. M., Chastre, J. E., Citerio, G., Conti, G., Curtis, J. R., Backer, D. D., Hedenstierna, G., Joannidis, M., Macrae, D. J., et al. (2012) · Intensive Care Medicine · doi:10.1007/s00134-012-2467-6 · Cited by 42
“These results are in accordance with those obtained by other investigators in patients with MRSA bloodstream infections [40].”
ResultAmpe, E., Delaere, B., Hecq, J., Tulkens, P. M., & Glupczynski, Y. (2013) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2013.01.009 · Cited by 42
Tamma, P. D., Holmes, A. H., & Ashley, E. D. (2014) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000077 · Cited by 42
Moore, C. L., Lü, M., Cheema, F., Osaki-Kiyan, P., Perri, M. B., Donabedian, S. M., Haque, N. Z., & Zervos, M. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00115-11 · Cited by 43
The Effect of Age and Weight on Vancomycin Serum Trough Concentrations in Pediatric Patients
Madigan, T., Sieve, R. M., Graner, K. K., & Banerjee, R. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1331 · Cited by 44
“However, vancomycin treatment failures have been reported for MRSA isolates with higher vancomycin minimum inhibitory concentrations (MIC) and in patients with lower serum vancomycin trough concentrations.(4) These observations, combined with the poor penetration of vancomycin into bone, lung, and the central nervous…”
BackgroundPark, H. J., Kim, S., Kim, M.-J., Lee, Y., Park, S.-Y., Moon, S. M., Park, K., Chong, Y. P., Lee, S., Choi, S., et al. (2012) · Journal of Infection · doi:10.1016/j.jinf.2012.08.007 · Cited by 41
Hirano, R., Sakamoto, Y., Kitazawa, J., Yamamoto, S., & Tachibana, N. (2016) · Infection and Drug Resistance · doi:10.2147/idr.s109485 · Cited by 40
Lodise, T. P., & Drusano, G. L. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1744 · Cited by 39
Chen, S., Liao, C., Wang, J., Chiang, W., Lai, M., Chie, W., Chen, W., Chang, S., & Hsueh, P. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis717 · Cited by 40
“anti-MRSA therapy [34–36].”
Review of Continuous-Infusion Vancomycin
DiMondi, V. P., & Rafferty, K. D. (2013) · Annals of Pharmacotherapy · doi:10.1345/aph.1r420 · Cited by 45
Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients
Hadi, O. A., Omar, S. A., Nazer, L. H., Mubarak, S., & Lê, J. (2015) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155215591386 · Cited by 43
Katip, W., & Oberdorfer, P. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091378 · Cited by 38
“Furthermore, the area under the curve of the vancomycin concentration-time graph above the minimum inhibitory concentration (AUC/MIC) is the pharmacokinetic (PK)/pharmacodynamic (PD) parameter that best correlates with favorable outcomes of invasive MRSA infections [5,6].”
BackgroundLiu, M., Yang, Z., & Li, G. (2018) · Molecules · doi:10.3390/molecules23112939 · Cited by 38
High-Dose Daptomycin and Clinical Applications
Jones, T. W., Jun, A. H., Michal, J. L., & Olney, W. J. (2021) · Annals of Pharmacotherapy · doi:10.1177/1060028021991943 · Cited by 42
Zelenitsky, S. A., Ariano, R. E., McCrae, M. L., & Vercaigne, L. M. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis458 · Cited by 37
Dubée, V., Zeller, V., Lhotellier, L., Kitzis, M.-D., Ziza, J.-M., Mamoudy, P., & Desplaces, N. (2012) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12071 · Cited by 37
“This finding agrees with several studies showing that high vancomycin doses increased the risk of nephrotoxicity [29–31].”
BackgroundResultVancomycin-Associated Acute Kidney Injury in a Large Veteran Population
Gyamlani, G. G., Potukuchi, P. K., Thomas, F., Akbilgiç, O., Soohoo, M., Streja, E., Naseer, A., Sumida, K., Molnar, M. Z., Kalantar‐Zadeh, K., et al. (2019) · American Journal of Nephrology · doi:10.1159/000496484 · Cited by 38
Goldmann, O., Cern, A., Müsken, M., Rohde, M., Weiss, W., Barenholz, Y., & Medina, E. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.11.007 · Cited by 38
Chen, S., Liao, C., Wang, J., Chiang, W., Lai, M., Chie, W., Chang, S., & Hsueh, P. (2013) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt340 · Cited by 36
Kullar, R., Davis, S. L., Kaye, K. S., Levine, D. P., Pogue, J. M., & Rybak, M. J. (2013) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1220 · Cited by 34
“However, we have previously described the association between initial vancomycin trough concentrations ( 15 mg/L) and treatment success in a cohort of more than 300 patients with confirmed MRSA bacteremia.(11) In the present study, patients in phase II received vancomycin for a median of 3 days before being switched t…”
BackgroundSelf-citationPharmacokinetic Assessment of Vancomycin Loading Dose in Critically Ill Patients
Álvarez, O., Plaza‐Plaza, J. C., Ramírez, M. M., Peralta, A. B., Amador, C. A., & Amador, R. (2017) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00280-17 · Cited by 40
Dinu, V. T., Lu, Y., Weston, N., Lithgo, R. M., Coupe, H., Channell, G. A., Adams, G. G., Torcello‐Gómez, A., Sabater, C., Mackie, A. R., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-57776-3 · Cited by 39
Wi, Y. M., Kim, J. M., Joo, E., Ha, Y. E., Kang, C., Ko, K. S., Chung, D. R., Song, J., & Peck, K. R. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2012.04.003 · Cited by 37
Prospective evaluation of vancomycin pharmacokinetics in a heterogeneous critically ill population
Turner, R. B., Kojiro, K., Won, R., Chang, E., Chan, D., & Elbarbry, F. (2018) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2018.06.022 · Cited by 33
The use and risks of antibiotics in critically ill patients
Denny, K. J., Cotta, M. O., Parker, S. L., Roberts, J. A., & Lipman, J. (2016) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1164690 · Cited by 33
“Although a PK/PD target of AUC0-24/MIC of 400 for vancomycin is generally thought to be efficacious for organisms such as methicillin-resistant Staphylococcus aureus (MRSA), [24,25] significant shifts to higher MICs for the same organism, described as MIC creep,[26] means that these targets might not be achievable wit…”
BackgroundHassan, M. M., Ranzoni, A., Phetsang, W., Blaskovich, M. A. T., & Cooper, M. A. (2016) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.6b00494 · Cited by 33
Periprosthetic Joint Infection of the Hip and Knee
Springer, B. D., & Parvizi, J. (2013) · Springer eBooks · doi:10.1007/978-1-4614-7928-4 · Cited by 35
Brink, A. J. (2012) · Current Opinion in Critical Care · doi:10.1097/mcc.0b013e3283578968 · Cited by 35
Joson, J., Grover, C. A., Downer, C., Pujar, T., & Heidari, A. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr234 · Cited by 31
Forstner, C., Dungl, C., Tobudic, S., Mitteregger, D., Lagler, H., & Burgmann, H. (2013) · Clinical Microbiology and Infection · doi:10.1111/1469-0691.12169 · Cited by 32
“5 mg/L or 2 mg/L appeared to be an important boundary indicating imminent clinical failure [8] or increased mortality in bloodstream infections, retrospectively [9].”
BackgroundMethodHigh-Dose Daptomycin Therapy for Staphylococcal Endocarditis and When to Apply It
Smith, J. R., Claeys, K. C., Barber, K. E., & Rybak, M. J. (2014) · Current Infectious Disease Reports · doi:10.1007/s11908-014-0429-6 · Cited by 31
“However, even with proper monitoring, IE has been implicated as an independent predictor of vancomycin treatment failure [11].”
Self-citationRose, W. E., Fallon, M. J., Moran, J. J. M., & Vanderloo, J. P. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00676-12 · Cited by 32
Ortwine, J. K., & Bhavan, K. (2018) · Hospital Practice · doi:10.1080/21548331.2018.1435128 · Cited by 38
The clinical efficacy and safety of vancomycin loading dose
Mei, H., Wang, J., Che, H., Wang, R., & Cai, Y. (2019) · Medicine · doi:10.1097/md.0000000000017639 · Cited by 28
Hall, R. G., Giuliano, C. A., Haase, K. K., Hazlewood, K. A., Frei, C. R., Forcade, N. A., Brouse, S. D., Bell, T., Bedimo, R., & Álvarez, C. A. (2012) · BMC Infectious Diseases · doi:10.1186/1471-2334-12-104 · Cited by 28
“Utilizing in-hospital mortality as our primary endpoint resulted in fewer events than utilizing 30 day mortality or vancomycin failure [15-17].”
Optimizing Antibiotic Pharmacodynamics for Clinical Practice
Connors, K. P. (2013) · Pharmaceutica Analytica Acta · doi:10.4172/2153-2435.1000214 · Cited by 33
Glycopeptide antibiotics: evolving resistance, pharmacology and adverse event profile
Henson, K. E. R., Levine, M. T., Wong, E. A. H., & Levine, D. P. (2015) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2015.1068118 · Cited by 33
“A single-center retrospective analysis of 320 patients demonstrated a 53% failure rate in patients initially treated with vancomycin for MRSA bacteremia [50].”
Self-citationKok, E. Y., Vallejo, J. G., Sommer, L. M., Rosas, L., Kaplan, S. L., Hultén, K. G., & McNeil, J. C. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00084-18 · Cited by 28
“5 g/ml was independently associated with vancomycin failure (19).”
BackgroundKomoto, A., Maiguma, T., Teshima, D., Sugiyama, T., & Haruki, Y. (2018) · PLoS ONE · doi:10.1371/journal.pone.0203453 · Cited by 29
Sample Cleanup Using Solid-Phase Dispersive Extraction for Determination of Vancomycin in Serum
Sakamoto, Y., Jinno, Y., Shinodzuka, I., Iwasaki, Y., Ito, R., & Saito, K. (2014) · Analytical Sciences · doi:10.2116/analsci.30.271 · Cited by 27
Relationship between vancomycin tolerance and clinical outcomes inStaphylococcus aureusbacteraemia
Britt, N. S., Patel, N., Shireman, T. I., Atrouni, W. E., Horvat, R. T., & Steed, M. E. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw453 · Cited by 33
El catéter periférico: el gran olvidado de la infección nosocomial
Capdevila, J. A. (2013) · Revista española de quimioterapia. Suplemento · Cited by 57
Vancomycin Pharmacokinetics in Obese Patients with Sepsis or Septic Shock
Masich, A. M., Kalaria, S. N., Gonzales, J. P., Heil, E. L., Tata, A. L., Claeys, K. C., Patel, D. M., & Gopalakrishnan, M. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2367 · Cited by 35
“7) SOFA score 11 (6, 17) qSOFA score 2 (2) Infection source Bacteremia 8 (50) Pneumonia 4 (25) Gastrointestinal 3 (19) Skin and soft tissue 1 (6) Bacteria isolated MRSA: 2 (13) CoNS: 4 (25) Streptococcus viridans: 1 (6) Staphylococcus hominis: 1 (6) Enterobacter cloacae: 1 (6) Candida albicans: 1 (6) Acinetobacter bau…”
Uda, A., Shigemura, K., Kitagawa, K., Osawa, K., Onuma, K., Yan, Y., Nishioka, T., Fujisawa, M., Yano, I., & Miyara, T. (2021) · Antibiotics · doi:10.3390/antibiotics10010064 · Cited by 28
“Higher vancomycin trough levels have been previously identified as a risk factor for nephrotoxicity [30], and thus, the longer duration of vancomycin use in the E.”
BackgroundKatip, W., Okonogi, S., & Oberdorfer, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.773994 · Cited by 26
“Moreover, the pharmacokinetic (PK)/pharmacodynamic (PD) parameter that correlate best with favorable outcomes of invasive MRSA infections are based on the area under the curve of the vancomycin concentration-time graph above the minimum inhibitory concentration (AUC/MIC) (Kullar et al., 2011a; Matsumoto et al., 2013).”
BackgroundChen, Y., Liu, C., Ko, W., Liao, C., Lu, P., Huang, C.-H., Lu, C.-T., Chuang, Y.-C., Tsao, S.-M., Chen, Y., et al. (2013) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-013-1949-y · Cited by 27
Wang, C., Ye, C., Liao, L., Wang, Z., Hu, Y., Deng, C., & Liu, L. (2020) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01377-20 · Cited by 29
“utility of VAN, including slow bactericidal activity, low tissue penetration, and increasing reports 58 of resistance and failure(6,7).”
AUCs and 123s: a critical appraisal of vancomycin therapeutic drug monitoring in paediatrics
Jorgensen, S. C. J., Dersch‐Mills, D., Timberlake, K., Stewart, J. J., Gin, A. S., Dresser, L., & Dalton, B. (2021) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkab048 · Cited by 30
Han, J., Mascitti, K. B., Edelstein, P. H., Bilker, W. B., & Lautenbach, E. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00757-12 · Cited by 27
“Along these lines, the association between RVS and poor clinical outcomes in patients receiving vancomycin has been attributed in part to difficulty achieving an optimal vancomycin area under curve (AUC)/MIC ratio (21).”
BackgroundLiu, P., Capitano, B., Stein, A., & El-Solh, A. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0581-y · Cited by 26
“In the face of “MIC creep” in MRSA isolates, a shift of Cmin from the traditional target of 5–15 μg/ml to a higher range of 15–20 μg/ml has been proposed in order to achieve vancomycin exposure in sufficient excess of the minimum concentration required to inhibit the organism [1, 7].”
BackgroundAugmented Renal Clearance of Vancomycin in Hematologic Malignancy Patients
Izumisawa, T., Kaneko, T., Soma, M., Imai, M., Wakui, N., Hasegawa, H., Horino, T., & Takahashi, N. K. (2019) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b19-00652 · Cited by 25
Vancomycin Dosing Considerations in a Real‐World Cohort of Obese and Extremely Obese Patients
Morrill, H. J., Caffrey, A. R., Noh, E., & LaPlante, K. L. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1625 · Cited by 25
Daptomycin Therapy for Osteomyelitis: A Retrospective Study
Gallagher, J. C., Huntington, J. A., Culshaw, D. L., McConnell, S. A., Yoon, M., & Berbari, E. F. (2012) · BMC Infectious Diseases · doi:10.1186/1471-2334-12-133 · Cited by 24
“aureus (MRSA) is becoming less susceptible to vancomycin, and has been associated with clinical failures when vancomycin is utilized [2-5].”
BackgroundFujii, S., Takahashi, S., Makino, S., Kunimoto, Y., Nakata, H., Noda, N., Sakurai, K., & Miyamoto, A. (2013) · Chemotherapy · doi:10.1159/000356756 · Cited by 24
Dosing of antibacterial agents in obese adults: does one size fit all?
Payne, K. D., & Hall, R. G. (2014) · Expert Review of Anti-infective Therapy · doi:10.1586/14787210.2014.912942 · Cited by 24
“While not a direct measure of vancomycin efficacy, vancomycin treatment failure has been associated with initial trough values <15 mg/l [43].”
BackgroundZhang, G., Zhang, N., Xu, J., Yang, T., Yin, H., & Cai, Y. (2023) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2023.106946 · Cited by 26
Stoessel, A. M., Hale, C. M., Seabury, R. W., Miller, C., & Steele, J. M. (2018) · Journal of Pharmacy Practice · doi:10.1177/0897190018764564 · Cited by 23
A Moving Target—Vancomycin Therapeutic Monitoring
Burns, A. N., & Goldman, J. L. (2020) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/piaa078 · Cited by 22
Balancing Vancomycin Efficacy and Nephrotoxicity: Should We Be Aiming for Trough or AUC/MIC?
Patel, K., Crumby, A. S., & Maples, H. D. (2015) · Pediatric Drugs · doi:10.1007/s40272-015-0117-5 · Cited by 23
O’Donnell, J. N., Rhodes, N. J., Miglis, C. M., Catovic, L., Liu, J., Cluff, C., Pais, G. M., Avedissian, S. N., Joshi, M. D., Griffin, B. L., et al. (2017) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2017.08.012 · Cited by 23
Hsu, A. J., Hamdy, R. F., Huang, Y., Olson, J. A., Ghobrial, S. S., Gerber, J. S., Hersh, A. L., & Tamma, P. D. (2017) · Journal of the Pediatric Infectious Diseases Society · doi:10.1093/jpids/pix068 · Cited by 23
Muklewicz, J., Steuber, T. D., & Edwards, J. D. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106234 · Cited by 23
Carreno, J. J., Kenney, R. M., Divine, G., Vázquez, J. A., & Davis, S. L. (2016) · Annals of Pharmacotherapy · doi:10.1177/1060028016673858 · Cited by 25
Self-citationChen, C., Li, M., Ma, L., Zhai, X., Luo, D., Zhou, Y. F., Liu, Z., & Cui, Y. (2020) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkaa150 · Cited by 22
Moorthy, G. S., Downes, K. J., Vedar, C., & Zuppa, A. F. (2020) · Bioanalysis · doi:10.4155/bio-2020-0112 · Cited by 22
Uçkay, İ., Bernard, L., Buzzi, M., Harbarth, S., François, P., Huggler, E., Ferry, T., Schrenzel, J., Renzoni, A., Vaudaux, P. E., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.05808-11 · Cited by 23
“Indeed, several clinical studies reported higher rates of vancomycin treatment failures and increased median times to bacteremic clearance in patients infected with either hVISA or MRSA isolates for which vancomycin MICs (2 g/ml) were at the upper limit of susceptibility than in those infected with isolates with lower…”
BackgroundGoldman, J. L., Harrison, C. J., Myers, A., Jackson, M. A., & Selvarangan, R. (2014) · The Pediatric Infectious Disease Journal · doi:10.1097/01.inf.0000436281.18687.0c · Cited by 22
A Systematic Review of Vancomycin Dosing and Monitoring in Burn Patients
Carter, B. L., Damer, K. M., Walroth, T. A., Buening, N. R., Foster, D. R., & Sood, R. (2014) · Journal of Burn Care & Research · doi:10.1097/bcr.0000000000000191 · Cited by 24
Vancomycin Trough and Acute Kidney Injury: A Large Retrospective, Cohort Study
Hammoud, K. A., Brimacombe, M. B., Yu, A. S. L., Goodloe, N., Haidar, W. N., & Atrouni, W. E. (2016) · American Journal of Nephrology · doi:10.1159/000452427 · Cited by 22
Reilly, A. M., Ding, M. X., Rower, J. E., & Kiser, T. H. (2019) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1392 · Cited by 22
“Neonates were included if they were (1) dosed according to the new vancomycin dosing guideline and had a vancomycin trough concentration (ie, concentrations from a sample collected within 30 minutes of the subsequent dose) sample collected in the NICU between September 2010 and December 2015 or (2) dosed according to…”
MethodOutcomes and Nephrotoxicity Associated with Vancomycin Treatment in Patients 80 Years and Older
Wang, Y., Dai, N., Wei, W., & Jiang, C. (2021) · Clinical Interventions in Aging · doi:10.2147/cia.s308878 · Cited by 22
Casapao, A. M., Davis, S. L., McRoberts, J. P., Lagnf, A. M., Patel, S., Kullar, R., Levine, D. P., & Rybak, M. J. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02820-13 · Cited by 22
“the onset of MRSA without another explanation, (iv) autopsy findings indicated MRSA as a cause of death, or (v) MRSA was indicated as a cause of death on the death certificate (12).”
BackgroundSelf-citationWoolever, N. L., Schomberg, R. J., Cai, S., Dierkhising, R., Dababneh, A. S., & Kujak, R. C. (2020) · Mayo Clinic Proceedings Innovations Quality & Outcomes · doi:10.1016/j.mayocpiqo.2020.05.002 · Cited by 23
“Mayo Clin Proc Inn Qual Out n October 2020 rg n a 2020 Mayo Foundation for Medical Education and Research the CC BY-NC-N vancomycin, has a substantial health care cost,(3) and treatment with vancomycin also carries an elevated risk of nephrotoxicity, thereby further increasing health care cost and hospital length of s…”
BackgroundSuzuki, A., Hamada, Y., Ikeda, H., Tanaka, H., Yanagihara, M., Namiki, M., Watanabe, T., & Sasaki, T. (2020) · Journal of Infection and Chemotherapy · doi:10.1016/j.jiac.2020.10.014 · Cited by 21
Edwards, B., Andini, R., Esposito, S., Grossi, P., Lew, D., Mazzei, T., Novelli, A., Soriano, À., & Gould, I. M. (2014) · Journal of Global Antimicrobial Resistance · doi:10.1016/j.jgar.2014.03.009 · Cited by 23
“pharmacodynamic predictor of vancomycin efficacy, and a value 400 is associated with higher success rates in patients with respiratory tract infections [46] and bacteraemia [5] and 600 in patients with septic shock [47].”
BackgroundMizokami, F., & Mizuno, T. (2014) · Drugs & Aging · doi:10.1007/s40266-014-0232-y · Cited by 25
Antimicrobial Treatment of Febrile Neutropenia: Pharmacokinetic–Pharmacodynamic Considerations
Goulenok, T. M., & Fantin, B. (2013) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0086-1 · Cited by 22
Matson, K. L., Shaffer, C. L., Beck, G. L., & Simonsen, K. A. (2015) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1552 · Cited by 21
Achievement of Therapeutic Vancomycin Exposure With Continuous Infusion in Critically Ill Children*
Genuini, M., Oualha, M., Bouazza, N., Moulin, F., Tréluyer, J., Lesage, F., Renolleau, S., & Benaboud, S. (2018) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000001474 · Cited by 23
Suzuki, Y., Tokimatsu, I., Morinaga, Y., Sato, Y., Takano, K., Kohno, K., Ogata, M., Hiramatsu, K., Itoh, H., & Kadota, J. (2014) · Clinica Chimica Acta · doi:10.1016/j.cca.2014.11.027 · Cited by 22
Murray, B. E., Arias, C. A., & Nannini, E. C. (2015) · Elsevier eBooks · doi:10.1016/b978-1-4557-4801-3.00030-8 · Cited by 27
Pericàs, J. M., Nathavitharana, R. R., García-de-la-Mària, C., Falces, C., Ambrosioni, J., Almela, M., García‐González, J., Quintana, E., Marco, F., Moreno, A., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00516-19 · Cited by 24
Metadata
- Authors
- Kullar, R., Davis, S. L., Levine, D. P., & Rybak, M. J.
- Affiliations
- Eugene Applebaum College of Pharmacy and Health Sciences (US)
- Wayne State University (US)
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-04-01
- Volume
- 52
- Issue
- 8
- Pages
- 975-981
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2099365065
- Semantic Scholar
- ed3c7f78a7e345dd4578c14051be67b5da32fd88
- Cited by
- 463
- References
- 44
- Citations by year
- 2026: 11 · 2025: 10 · 2024: 15 · 2023: 15 · 2022: 22 · 2021: 37 · 2020: 33 · 2019: 40 · 2018: 27 · 2017: 26 · 2016: 30 · 2015: 37 · 2014: 43 · 2013: 57 · 2012: 45
- FWCI
- 34.30
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Pfizer
- Astellas Pharma
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antimicrobial Resistance in Staphylococcus
- Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Keywords
- vancomycin, methicillin-resistant Staphylococcus aureus, MRSA bacteremia, pharmacokinetic/pharmacodynamic targets, AUC/MIC ratio, trough concentration, infective endocarditis, nosocomial infections, antimicrobial susceptibility testing, E-test, broth microdilution
- MeSH terms
- Anti-Bacterial Agents, Humans, Microbial Sensitivity Tests, Middle Aged, Retrospective Studies, Staphylococcal Infections, Vancomycin, Bacteremia, Treatment Outcome, Guidelines as Topic, Methicillin-Resistant Staphylococcus aureus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.